The estimated Net Worth of Michael J Brooks is at least $561 Mille dollars as of 29 June 2022. Dr Brooks owns over 3,000 units of Edesa Biotech stock worth over $114,673 and over the last 5 years he sold EDSA stock worth over $0. In addition, he makes $446,089 as Pres at Edesa Biotech.
Sign up
Dr D EDSA stock SEC Form 4 insiders trading
Dr has made over 10 trades of the Edesa Biotech stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 3,000 units of EDSA stock worth $4,470 on 29 June 2022.
The largest trade he's ever made was buying 4,500 units of Edesa Biotech stock on 24 March 2021 worth over $22,860. On average, Dr trades about 1,266 units every 45 days since 2019. As of 29 June 2022 he still owns at least 26,241 units of Edesa Biotech stock.
You can see the complete history of Dr Brooks stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Michael J. Brooks M.B.A., Ph.D. biography
Dr. Michael J. Brooks M.B.A., Ph.D. is the Pres at Edesa Biotech.
What is the salary of Dr D?
As the Pres of Edesa Biotech, the total compensation of Dr D at Edesa Biotech is $446,089. There are 1 executives at Edesa Biotech getting paid more, with Dr. Pardeep Nijhawan FRCPC, M.D. having the highest compensation of $498,773.
How old is Dr D?
Dr D is 43, he's been the Pres of Edesa Biotech since . There are 2 older and no younger executives at Edesa Biotech. The oldest executive at Edesa Biotech, Inc. is Kathi Niffenegger CPA, CPA, 64, who is the Chief Financial Officer.
What's Dr D's mailing address?
Michael's mailing address filed with the SEC is C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM, A6, L3R 5H6.
Insiders trading at Edesa Biotech
Over the last 5 years, insiders at Edesa Biotech have traded over $856,596 worth of Edesa Biotech stock and bought 247,412 units worth $776,447 . The most active insiders traders include Der Velden Peter Lumira Cap..., Pardeep Pardeep Nijhawan Me... e Jennifer M Chao. On average, Edesa Biotech executives and independent directors trade stock every 50 days with the average trade being worth of $73,455. The most recent stock trade was executed by Pardeep Pardeep Nijhawan Me... on 25 March 2024, trading 5,000 units of EDSA stock currently worth $20,000.
What does Edesa Biotech do?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
What does Edesa Biotech's logo look like?
Complete history of Dr Brooks stock trades at Edesa Biotech
Edesa Biotech executives and stock owners
Edesa Biotech executives and other stock owners filed with the SEC include:
-
Dr. Pardeep Nijhawan FRCPC, M.D.,
CEO, Company Sec. & Director -
Dr. Michael J. Brooks M.B.A., Ph.D.,
Pres -
Kathi Niffenegger CPA, CPA,
Chief Financial Officer -
Rajan Puri,
Sr. VP of Manufacturing -
Gary Koppenjan,
VP of Investor Relations & Communications -
Patrick Marshall,
-
Stephen Lemieux,
Chief Financial Officer -
Joan Chypyha,
-
Charles V Olson,
-
Lorin K Johnson,
-
Carlo Sistilli,
-
Kathi Niffenegger,
Chief Financial Officer -
Der Velden Peter Lumira Cap...,
-
Jennifer M Chao,
-
Frank R. Oakes,
-
Pardeep Pardeep Nijhawan Me...,
Chief Executive Officer -
Paul William Pay,
-
Der Velden Peter Van,
-
Sean Arthur Mac Donald,
-
Michael J Brooks,
President -
Pardeep Nijhawan,
Chief Executive Officer